You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.
We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!
There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.
Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.
While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.
This report is drawn from STAT’s pop-up newsletter, “AACR in 30 seconds,” summarizing highlights from the American Association for Cancer Research annual meeting.
It represents the final edition of that popup series and references STAT+ subscriber content and a current promotional offer.
No further methodological detail about the newsletter itself is provided.
Revolution Medicines held sessions that attracted large audiences at the meeting.
Media attention concentrated on daraxonrasib data in first‑line pancreatic cancer, which was the most widely reported element of their presentations.
Company leadership disclosed initial activity for a compound designated RM‑055.
The CEO characterized RM‑055 as belonging to a proposed class of “catalytic inhibitors.” According to that description, RM‑055 can remove a phosphate from GTP‑RAS (the active “on” form of RAS), thereby inactivating the protein.
Interest in RM‑055 stems from a resistance mechanism to current RAS inhibitors: tumor cells may amplify mutant RAS alleles, increasing levels of the active oncoprotein to overwhelm inhibitors.
A compound with catalytic activity that can inactivate multiple mutant RAS molecules could, in principle, address that amplification strategy.
The source indicates that Revolution Medicines “revealed some activity” for RM‑055 but does not provide quantitative data, trial design, patient population, safety findings, or peer‑reviewed results.
Details of experiments, endpoints, or stages of development are not reported in the provided content.
Key experimental and clinical information—such as magnitude of effect, dosing, safety profile, trial phase, and independent validation—are absent from the source.